Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial

Background: In the phase III AVAGAST trial, the addition of bevacizumab to chemotherapy improved progression-free survival (PFS) but not overall survival (OS) in patients with advanced gastric cancer. We studied the role of Angiopoietin-2 (Ang-2), a key driver of tumour angiogenesis, metastasis and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2016-04, Vol.114 (8), p.855-862
Hauptverfasser:	Hacker, Ulrich T, Escalona-Espinosa, Laura, Consalvo, Nicola, Goede, Valentin, Schiffmann, Lars, Scherer, Stefan J, Hedge, Priti, Van Cutsem, Eric, Coutelle, Oliver, Büning, Hildegard
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1504/1829 692/308/2779/109/1942 692/699/67/1857 692/699/67/322 Adult Aged Angiogenesis Inhibitors - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab - administration & dosage Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Clinical Study Disease-Free Survival Drug Resistance Epidemiology Female Humans Male Middle Aged Molecular Medicine Neoplasm Metastasis - diagnosis Oncology Prognosis Stomach Neoplasms - blood Stomach Neoplasms - diagnosis Stomach Neoplasms - drug therapy Vesicular Transport Proteins - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!